Escitalopram co-prescription in anastrozole-treated breast cancer patients

Ozyurt H., Ozden S., Gemici C., Kucukibrahimoglu E., Odabas H., NEŞETOĞLU N., ...Daha Fazla

NORTHERN CLINICS OF ISTANBUL, cilt.9, sa.3, ss.248-255, 2021 (ESCI, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.14744/nci.2022.48264
  • Dergi Adı: NORTHERN CLINICS OF ISTANBUL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.248-255
  • Anahtar Kelimeler: Anastrozole, breast cancer, escitalopram, obesity, therapeutic drug monitoring, BODY-MASS INDEX, AROMATASE INHIBITORS, POSTMENOPAUSAL WOMEN, IN-VITRO, DEPRESSION, PHARMACOKINETICS, TAMOXIFEN, OBESITY, METABOLISM, IMPACT
  • İstanbul Üniversitesi Adresli: Evet

Özet

OBJECTIVE: The purpose of the study was to evaluate the impact of escitalopram co-prescription on plasma anastrozole levels in post-menopausal breast cancer patients.